OncoPharm

VIALE-A: Veneoxlax + azacitidine, a new standard of care for elderly or unfit AML patients, is now published. Lots of supportive care and management concerns to discuss: tumor lysis syndrome, prophylactic anti-microbials, G-CSF use (?), and dose modification for hematologic toxicity. Link: https://doi.org/10.1056/nejmoa2012971

Lots of new options for B-cell malignancies of all ages! We discuss brexucabtagene autoleucel (CAR-T for mantle cell lymphoma, tafasitamab (anti CD-19 monoclonal antibody), and belantamab mafadotin (anti-BCMA antibody drug conjugate). Finally, for good measure we review the newly approved regimen of atezolizumab with vemurafenib/cobimetinib for BRAF-mutated metastatic melanoma.

Dive into the world of gemcitabine, a pivotal chemotherapy drug effectively targeting solid tumors such as pancreatic and breast cancer. Explore its intricate pharmacology and recommended dosing, alongside vital safety considerations for patients with liver issues. The conversation also delves into comparisons with cytarabine, highlighting gemcitabine's unique role in oncology. Tune in for a comprehensive look at this essential treatment in cancer care.

We summarize the changes to ASCO's latest Antiemetic Guidelines update as well as their guidelines for chemotherapy-induced peripheral neuropathy (CIPN). Then, we take a look at the PO decitabine approval and ponder the question, does low albumin decrease tolerability to some TKIs?

We're joined by Dr. Karen Fancher, oncology pharmacist, to talk about her breast cancer story from diagnosis to shared-decision making treatment plans with her oncologist to treatment toxicity.

Dive into the essentials of neutropenic fever, an urgent oncologic emergency. Learn about its definition, causes, and risk factors. The discussion emphasizes the importance of timely antibiotic treatment and how it can make a difference in patient outcomes. Discover key indicators that clinicians should watch for and the need for personalized treatment approaches. Plus, explore insights from the impactful How Long study that may surprise even seasoned practitioners!

FDA ended June with 5 new approvals. *selinexor for r/r DLBCL *pembrolizumab for cutaneous squamous cell carcinoma *pembrolizumab for MSI-h/dMMR met. colorectal cancer *avelumab maintenance for met. bladder cancer *SC trastuzumab/pertuzumab/hyaluronidase

Dive into the essentials of clinical trial endpoints in oncology! Discover the significance of overall survival and quality of life as key priorities. Explore when to use overall survival metrics, and understand the nuances of progression-free survival. Learn about the role of surrogate endpoints and their impact on trial results. John Bazar breaks down disease-free and event-free survival concepts, while also highlighting response rates in various treatment scenarios like CAR-T. It's an informative ride perfect for newcomers to oncology!

Topics on this week's Pod include: -Lurbinectedin in SCLC -Nivolumab is esophageal cancer -Pembrolizumab for TMB-high cancers -Gemtuzumab ozogamicin for pediatric AML -Venetoclax + HMA for adult (unfit) AML -Gardasil for prevention of SCCHN -Perhaps the biggest non-oncopharm news of the year?

LD Vs Ld by John Bossaer